Pomerantz Law Firm Launches Investigation for PepGen Investors Amid Regulatory Concerns
On March 19, 2026, Pomerantz LLP announced it is investigating claims on behalf of investors of PepGen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol PEPG. The investigation aims to determine if PepGen, along with its executives or board members, may have participated in securities fraud or other illegal business practices. This comes in the wake of recent developments that significantly impacted the company's stock performance.
The backdrop for Pomerantz's investigation was set on March 4, 2026, when PepGen disclosed that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 clinical trial. This trial is crucial as it evaluates PGN-EDODM1, a promising treatment for patients diagnosed with myotonic dystrophy type 1 (DM1). The FDA's hold raised serious questions concerning the integrity of the preclinical pharmacology and toxicology studies that had been submitted by the company. This unexpected regulatory scrutiny not only prompted safety evaluations but also put PepGen's development timeline and future prospects at risk.
Following this negative announcement, PepGen's stock price took a considerable hit, plunging $1.25, or approximately 18.57%, to close at $5.50 on March 5, 2026. Such a dramatic drop highlights the potential consequences of failing to address and remediate issues flagged by regulatory bodies, especially when those issues may not have been previously disclosed to investors.
In light of these events, Pomerantz LLP is encouraging shareholders to reach out if they believe they have been harmed by PepGen's actions or lack thereof. Investors have been advised to get in touch with Danielle Peyton at the firm's office or through the provided contact telephone number. They can also join a class-action lawsuit, should it be established, as there may be a collective interest in addressing the implications of PepGen's communications, or lack thereof, with the investment community.
Pomerantz LLP has built a solid reputation over the past 85 years, known for its commitment to fighting for victims of securities fraud and corporate misconduct. The firm was founded by Abraham L. Pomerantz, who set the groundwork for what is now a leading practice in corporate and securities class action litigation. They have successfully recovered millions of dollars for class members affected by illegal business activities and promise to pursue justice for those impacted by PepGen's actions.
Investors should stay informed about the developments regarding PepGen, especially as these legal actions unfold. It is crucial for all affected parties to seek appropriate legal counsel to understand their rights and the avenues available to them. In an industry that can change rapidly based on regulatory interactions, being proactive can make a significant difference in the outcomes for shareholders facing potential losses.
The backdrop for Pomerantz's investigation was set on March 4, 2026, when PepGen disclosed that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 clinical trial. This trial is crucial as it evaluates PGN-EDODM1, a promising treatment for patients diagnosed with myotonic dystrophy type 1 (DM1). The FDA's hold raised serious questions concerning the integrity of the preclinical pharmacology and toxicology studies that had been submitted by the company. This unexpected regulatory scrutiny not only prompted safety evaluations but also put PepGen's development timeline and future prospects at risk.
Following this negative announcement, PepGen's stock price took a considerable hit, plunging $1.25, or approximately 18.57%, to close at $5.50 on March 5, 2026. Such a dramatic drop highlights the potential consequences of failing to address and remediate issues flagged by regulatory bodies, especially when those issues may not have been previously disclosed to investors.
In light of these events, Pomerantz LLP is encouraging shareholders to reach out if they believe they have been harmed by PepGen's actions or lack thereof. Investors have been advised to get in touch with Danielle Peyton at the firm's office or through the provided contact telephone number. They can also join a class-action lawsuit, should it be established, as there may be a collective interest in addressing the implications of PepGen's communications, or lack thereof, with the investment community.
Pomerantz LLP has built a solid reputation over the past 85 years, known for its commitment to fighting for victims of securities fraud and corporate misconduct. The firm was founded by Abraham L. Pomerantz, who set the groundwork for what is now a leading practice in corporate and securities class action litigation. They have successfully recovered millions of dollars for class members affected by illegal business activities and promise to pursue justice for those impacted by PepGen's actions.
Investors should stay informed about the developments regarding PepGen, especially as these legal actions unfold. It is crucial for all affected parties to seek appropriate legal counsel to understand their rights and the avenues available to them. In an industry that can change rapidly based on regulatory interactions, being proactive can make a significant difference in the outcomes for shareholders facing potential losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.